In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?

With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.

BioPharmaceutical Cancer Innovation

Podcast: The Trump Factor – Current And Potential Changes For US Medtech

In this free podcast, In Vivo asks AdvaMed government affairs director JC Scott what the medical technology industry hopes for, expects, and fears from the new Republican US president.

United States US Election 2016 Medical Device

Schilsky On ASCO 2017: The “You” Factor In Cancer Care

ASCO’s 2017 annual meeting is expanding its focus on patient wellness beyond the clinic, with new research highlighting prevention, alternative treatments post-surgery, psycho-social factors and other issues reflecting the concerns of a growing new constituency of cancer survivors. In Vivo discusses this year’s agenda with ASCO’s CMO, Richard Schilsky.

BioPharmaceutical Cancer Market Access
Advertisement


 

Recent Tweets from In Vivo


 

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Finding The Right Path To Category Leadership In Oncology

Oncology drug development is undergoing rapid shifts. Bain research shows companies that seek to lead in specific vertical categories outperform rivals that invest across a broad spectrum of cancer targets.

Business Strategies Growth

Regression To The Meanest: How Markets Value Pharma Stocks

Financial markets – the people and institutions that lend companies money and estimate their worth – see pharma companies as revenue-generating, profit-sharing black boxes. Growth earns companies a break from this simplistic view, but sooner or later market valuations of pharmas seem to regress to a mean based on revenue multiples. That mean is getting meaner.

Business Strategies Financing

Managing Pharma's Competing Challenges In The New Health Economy

The shifts roiling the health care industry are creating an entirely new commercial landscape. PwC says that the way pharma companies opt to address three pivotal challenges – patient engagement, analytics and value – will affect not only their future, but the future direction of patient care, provider decisions and payment mechanisms.

Business Strategies Pricing Strategies

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

When Two Worlds Collide – BTG Brings Interventional Oncology And Immunotherapy Together

BTG's range of interventional oncology technologies puts it in an enviable position in R&D initiatives that require a holistic view across cancer and the best-targeted therapies. The UK-listed company will now take this to another level following an agreement with the Society of Interventional Oncology to explore the role of minimally invasive therapies in immuno-oncology.

ImmunoOncology Research and Development Strategies

Can Artificial Intelligence Help Find Better Medicines?

Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.

BioPharmaceutical Innovation

Germany's New High-Risk Assessment Medtech Scheme Off To Slow Start

Germany's new testing and treatment methods (NUBs) scheme for assessing benefit in high-risk products for inpatient use recently processed its first batch of applications. But, as with its longer-established outpatient products counterpart, it does not seem to be an instant success, says German reimbursement expert Ben Modley.

Health Technology Assessment Medical Device

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, May 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments BioPharmaceutical

With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Business Strategies Cancer

Podcast: Trump's 100 Day Test

Trump-watchers, check out our new podcast covering Trump's first months in office and the full GOP policy agenda. (Free with registration.)

BioPharmaceutical US Election 2016

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

EU Medtechs Keep Open Mind On HTA Options In Wider Market Access Plan

Health technology assessment for medtech products in Europe is a strictly national responsibility, but is there a case for an EU-wide HTA system that could improve medtech market access? MedTech Europe chief executive Serge Bernasconi shares his views with In Vivo.

Health Technology Assessment Policy & Regulation

WannaCry Cybersecurity Alert Shows Medtech Software Must Look Beyond Quick Fixes

Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.

Digital Health Commercial

CAR-T Cancer Drugs Front And Center At ARM Investor Day

Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.

Regenerative Medicine Commercial

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Innovation In Oncology: An Infographic

Free article. Oncology innovation: lots of drugs, lots of trials, sometimes not enough patients. And styles of innovation depend on whether a company has a big franchise to defend or would like one. In Vivo presents current data on sales, pipelines, trials and fails.

BioPharmaceutical Cancer

Biopharma Quarterly Deal-Making Statistics, Q1 2017

Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.

BioPharmaceutical Deals

US Biosimilars: Busting Blockbusters Or Managing Obsolescence?

As a new generation of biosimilars challenge some of pharma’s biggest-selling products, this In Vivo analysis looks at how the originator blockbuster might fare in the face of competition. Experience in Europe, which predates that in the US by about a decade, provides a number of crucial pointers to outcomes and defensive strategies.

Biosimilars Biologics
UsernamePublicRestriction

Register